• April 15, 2021

EpimAb Biotherapeutics Raises $120M in Series C Financing to Advance Bispecific Programs and Broaden Clinical Pipeline - Odessa American: Business

e-Edition Subscribe

EpimAb Biotherapeutics Raises $120M in Series C Financing to Advance Bispecific Programs and Broaden Clinical Pipeline

Print
Font Size:
Default font size
Larger font size

Posted: Monday, March 22, 2021 6:00 pm

SHANGHAI--(BUSINESS WIRE)--Mar 22, 2021--

EpimAb Biotherapeutics, a clinical stage biotech company specializing in bispecific antibody development, announced today the closing of a $120 million Series C financing round. The round was co-led by China Merchants Bank International (CMBI) and Mirae Asset Financial Group (Mirae), and joined by Hony Capital, Cormorant Asset Management, Yanchuang Capital, Octagon Capital, renowned cultural entrepreneur and investor Adrian Cheng and ShangBay Capital, with strong participation from existing investors such as Decheng Capital, SDIC Fund, Sherpa Healthcare Partners, and Hidragon Capital. Proceeds from the financing will be used to fund the ongoing clinical development of EMB-01, EMB-02 and EMB-06, and to expand the company’s pipeline of novel bispecific antibodies and other biologics. Tony Rong, nominated by CMBI, and Sungwon Song, nominated by Mirae, will also join the EpimAb Board of Directors.

“The completion of our Series C financing will enable us to accelerate the development of our three clinical assets EMB-01, EMB-02 and EMB-06, and to advance our rich pipeline of preclinical programs into the clinic as we continue to build on our portfolio of novel bispecific antibodies generated based on our proprietary FIT-Ig technology,” said Dr. Chengbin Wu, founder and CEO of EpimAb Biotherapeutics. “With three candidates currently progressing through clinical trials and several ongoing high-value development projects in the pipeline poised to move towards the clinic, we are confident in our development strategy and our potential for long-term value generation. We greatly appreciate the support from our new and current investors as we move into this next phase of our company’s development and remain committed to bringing innovative bispecific antibody therapeutics to patients worldwide.”

EpimAb is creating a pipeline of novel proprietary bispecific antibody therapeutics with a focus on oncology and other areas of high value to patients. EMB-01, EpimAb’s lead candidate designed to simultaneously target EGFR and cMET on tumor cells, is currently progressing through a Phase I/II clinical study in both China and the U.S. EMB-02, EpimAb’s second clinical candidate, which simultaneously targets two checkpoint proteins, PD-1 and LAG-3, and has shown strong anti-tumor activities in preclinical models resistant to standard anti-PD-1 monotherapies, recently received FDA clearance to progress into the clinic in the U.S. EMB-06, a T cell engaging bispecific designed to simultaneously target CD3 and BCMA with differentiated properties, has been cleared to initiate clinical trials in Australia.

“EpimAb is among the premier innovative biopharmaceutical companies in China, revolutionizing the bispecific antibody space with a proprietary technology that has global potential,” said Tony Rong. “As we continue to expand our global life sciences portfolio, CMBI is committed to support EpimAb’s mission of bringing novel bispecific therapeutics to patients.”

“Each of EpimAb’s assets impressed us with enormous potential and a unique approach to treating areas of high unmet medical need. EpimAb’s dedicated pipeline of bispecific antibodies with best-in-class mechanisms makes it one of the driving forces behind Chinese biopharma innovations,” said Sungwon Song. “Mirae is excited to be a part of the company’s rapid evolution to become a global leader in its space.”

About EpimAb Biotherapeutics, Inc.

EpimAb Biotherapeutics is a privately-owned biopharmaceutical R&D company with research and manufacturing facilities in Shanghai and Suzhou with a proprietary unique and efficient technology called FIT-Ig® (Fabs-In-Tandem Immunoglobulin) to generate bispecific molecules with antibody-like properties. With this platform EpimAb is creating a pipeline of its own novel bispecific antibody therapeutics focused around immuno-oncology and other areas of high value to patients. EpimAb is also committed to diversifying its pipeline through selective licensing of its platform and pipeline assets to partners worldwide. For further information, please visit www.epimab.com

View source version on businesswire.com:https://www.businesswire.com/news/home/20210322005812/en/

CONTACT: EpimAb Biotherapeutics

In the U.S.:

Dr. Stephan Lensky, COO/CBO

Direct: +1 978-870-6276

Stephan.lensky@epimab.com

In China:

Dr. David Gu, CFO

Direct: +86-21-61951011

David.gu@epimab.com

Dr. Jason Tang,BD Director

Direct: +86-21-61951014

yesheng.tang@epimab.com

Media Inquiries

MacDougall

Amanda Houlihan or Emily Wong

+1 781-235-3060

epimab@macbiocom.com

KEYWORD: CHINA ASIA PACIFIC

INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH CLINICAL TRIALS

SOURCE: EpimAb Biotherapeutics

Copyright Business Wire 2021.

PUB: 03/22/2021 07:00 PM/DISC: 03/22/2021 07:00 PM

http://www.businesswire.com/news/home/20210322005812/en

© 2021 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Odessa, TX

Current Conditions

Cloudy
50°
Humidity: 89%
Winds: ENE at 13mph
Feels Like: 45°

Your Extended Forecast

Today

weather
High 57°/Low 49°
Scattered thunderstorms possible. Lows overnight in the upper 40s.

Tomorrow

weather
High 68°/Low 59°
Morning showers and thunderstorms. Highs in the upper 60s and lows in the upper 50s.

friday

weather
High 78°/Low 40°
Mostly cloudy. Highs in the upper 70s and lows in the low 40s.

saturday

weather
High 56°/Low 40°
Cloudy. Highs in the mid 50s and lows in the low 40s.
Online Features

Pet Central

pets

Having a pet is a lot of responsibility, and we’ll help by giving you lots of tips and tricks! More >>

Fitness

Fitness

Our fitness articles will help teach you how to work out with gym- and home-based exercises. More >>

Crosswords

Crosswords

Enjoy the crosswords challenge in our free daily puzzles, from the harder Sunday crossword to the quicker daily. More >>

Sudoku

Sudoku

Every Sudoku has a unique solution that can be reached logically. Enter numbers into the blank spaces so that each row, column and 3x3 box contains the numbers 1 to 9. More >>




  • ALL-ACCESS: Subscribe to our e-edition and premium website at myoaoa.com.
    You can read your daily newspaper without taking a walk to the driveway.
    Look back at yesterday's newspaper, or issues from months ago with our archive feature.
    Call circulation at 432-337-7314 to sign up today.